Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kymera Therapeutics (NASDAQ: KYMR) is set to report its first quarter 2023 financial results on May 4, 2023, with a conference call scheduled for 8:30 a.m. ET. The company, known for its innovative approach to targeted protein degradation, has outlined its participation in several upcoming investor conferences, including Stifel Virtual Targeted Oncology Days on April 25, 2023, BofA Securities Health Care Conference on May 10, 2023, and Piper Sandler Spring Biopharma Symposium on May 18, 2023. Kymera’s drug discovery engine focuses on targeting disease-causing proteins and aims to advance its therapeutic pipeline for various diseases, including immune-inflammatory diseases and hematologic malignancies.
Kymera Therapeutics (NASDAQ: KYMR), a biopharmaceutical company focused on targeted protein degradation, has announced upcoming investor events. The management team will participate in the Cowen 43rd Annual Health Care Conference in Boston, MA from March 6-8, 2023, with CEO Nello Mainolfi presenting a fireside chat on March 6 at 10:30 AM ET, alongside hosting 1x1 meetings. Additionally, the Jefferies Biotech on the Bay Summit in Miami, FL will take place on March 16-17, 2023, where the company will conduct 1x1 meetings only. A live webcast of the fireside chat will be available on their website.